Cite
HARVARD Citation
Hortobagyi, G. et al. (2018). Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Annals of oncology. pp. 1541-1547. [Online].